These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A].
    Author: Wei Q, Li G, Tang L, Chen Z, Zhen Y, Wu X, Zhang N, Zhang J, Yu G, Wu R.
    Journal: Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):99-102. PubMed ID: 24739719.
    Abstract:
    OBJECTIVE: To study the current situation of coagulation factor VIII (FVIII) inhibitor development in children with hemophilia A (HA) through a cross-sectional survey, and to explore the risk factors of inhibitor development in order to provide evidence for further prevention and management strategies. METHOD: The clinical data of outpatients with hemophilia A in Beijing Children's Hospital seen from November 2012 to May 2013 were collected, FVIII inhibitor was screened and analyzed its risk factors. RESULT: A total of 102 HA children were enrolled, 5 were mild cases, 32 were moderate, and 65 were severe cases; the median age on enrollment was 55.5 (3.0-200.0) months:19(18.6%) of patients had inhibitors and 9 (8.8%) had low-titer inhibitors, 10 (9.8%) had high-titer inhibitors. Receiving FVIII treatment for life-threatening bleeding (P = 0.03) ,OR 4.10 (95%CI:1.17-14.32) was a risk factor for inhibitor generation and patients within 20 exposure days have more chances of inhibitor development (P = 0.04) ,OR 3.32 (95%CI:1.02-10.86) . High and intense FVIII exposure within short term was the risk factor for high titer inhibitor development (P = 0.01) ,OR 5.25 (95%CI:1.45-21.92) . CONCLUSION: Intense FVIII exposure for severe hemorrhage was the risk factor of inhibitors development especially of high titer inhibitors.
    [Abstract] [Full Text] [Related] [New Search]